Hello. This is Daily Stock.
On Tuesday, September 1, 2026, amid macroeconomic uncertainties and the Nasdaq index's search for direction, the biotechnology and pharmaceutical sectors are charting new valuation paths powered by pipeline innovation.
[Image: /stdaily/uploads/202609/gen_6a9615ec35fab2.88124108.png]
Key Summary
As of midday on September 1, 2026 (provisional), the Nasdaq index stood at 26,370.89, showing a breathing spell, while the Daily Stock Fear & Greed Index for the Nasdaq currently indicates Neutral (49.7).
Recently, large-cap pharmaceutical company Amgen (AMGN) raised its guidance on the back of solid earnings and is concentrating its capabilities on the Phase 3 clinical trial of its obesity treatment 'MariTide'.
Moderna (MRNA), which had been struggling with a sharp decline in vaccine demand post-pandemic, also delivered a powerful shock to the market by announcing the successful Phase 3 trial results of 'Intismeran', a personalized cancer vaccine co-developed with Merck.
Current Situation Summary
Amgen's flagship osteoporosis treatment, Prolia, faced biosimilar competition after June 2025, suffering a hit to sales ($759M, a 32% decrease). However, the company successfully defended its top line through high growth of the cholesterol treatment Repatha ($953M, a 37% increase).
Particularly in the obesity treatment market, anticipation for the Phase 3 trial of 'MariTide'—which is exploring monthly or quarterly administration, unlike existing GLP-1 therapies requiring weekly dosing—is firmly supporting the stock price.
Following the mid-August announcement that its personalized neoantigen cancer vaccine (mRNA-4157) met its Phase 3 melanoma endpoint, Moderna saw its stock price skyrocket by approximately 177% in a single day, confirming unprecedented market excitement.
After the surge, the stock experienced short-term profit-taking and adjustment phases, and is currently consolidating around the $139 level. The company recently secured funding for oncology pipeline development by deciding to issue $2 billion in zero-coupon convertible senior notes.
Financial Analysis
Amgen's Q2 2026 revenue increased approximately 10% year-over-year to $10.05 billion, beating the market expectation of $9.43 billion.
Non-GAAP earnings per share (EPS) also reached $6.29, significantly beating the consensus ($5.62). The company officially raised its full-year revenue guidance from $37.1B–$38.5B to $38.2B–$39.4B, and its EPS guidance to the $22.30–$23.50 range.
In contrast, Moderna's Q2 revenue stood at just $145 million due to the post-COVID fallout, recording a GAAP net loss of approximately $800 million (loss per share of $1.97), indicating a remaining heavy burden of fixed costs.
However, through structural improvements, the company is managing its projected year-end 2026 cash balance to be around $4.7 billion. By issuing $2 billion in zero-coupon convertible bonds maturing in 2032, it aims to secure additional R&D momentum despite dilution concerns.
| Classification | Amgen (AMGN) | Moderna (MRNA) |
|---|---|---|
| **Q2 2026 Revenue** | $10.05 Billion (YoY +10%) | $145 Million (Post-Pandemic) |
| **Q2 2026 Net Profit/Loss** | $6.29 per share (Non-GAAP, Beat) | -$1.97 per share (GAAP, Net Loss $800M) |
| **Full-Year 2026 Guidance** | Revenue: $38.2B ~ $39.4B / EPS: $22.30 ~ $23.50 | Expected year-end cash balance maintained at ~$4.7B |
| **Major Core Momentum** | MariTide Phase 3 entry and SWITCH trial initiation | Intismeran (mRNA-4157) Melanoma Phase 3 primary endpoint met |
| **Cash & Cash Equivalents** | $14 Billion (As of June 30, 2026) | Estimated ~$4.7 Billion (As of year-end 2026 guide) |
Valuation
With the Nasdaq 100's 12-month Forward Price-to-Earnings (Forward PER) ratio hovering around 21 to 22 times, Amgen's Forward PER sits around 15 to 16 times, enhancing its valuation appeal alongside a solid dividend (declaring $2.52 per quarter).
The risks of patent expiration and biosimilar competition for existing blockbuster drugs are being cleverly offset by the future value of new high-growth drugs and a robust obesity pipeline.
While Moderna's current net loss makes it difficult to evaluate using standard P/E ratios, expectations for the commercialization of its mRNA-based personalized cancer vaccine have become the core pillar of its valuation.
As the market value following the positive melanoma Phase 3 interim data has been rapidly priced in, valuation volatility is bound to remain highly elevated until its efficacy in other solid tumors is confirmed.
[Image: /stdaily/uploads/202609/gen_6a9615f697fd64.87471407.png]
Analyst & Institutional Analysis
Barclays recently viewed Amgen's stable revenue portfolio diversification positively and raised its price target from $360 to $380, while Cantor Fitzgerald maintained a Neutral rating but raised its target to $400.
The market is showing significant interest in the design of the 'SWITCH' Phase 3 clinical study, which evaluates patients currently on weekly GLP-1 drugs switching to Amgen's quarterly MariTide.
For Moderna, Bank of America (BofA) sharply raised its price target to $170, fully incorporating the disruptive commercialization potential of mRNA cancer vaccines into its analysis model.
Experts analyze that since the technical validation of cancer vaccines has been proven for the first time, the real test to justify the stock's multiple will now go beyond clinical results to actual FDA approval timelines and drug pricing strategies.
Risk Factors
First, there are concerns over a prolonged high-interest-rate environment for the US 10-Year Treasury Yield (US10Y).
Since the biotech sector's value is discounted based on far-future cash flows from prospective drug pipelines, a retreat in macroeconomic rate-cut expectations exerts downward pressure on growth stock multiples.
Second, there is binary risk due to reliance on a single pipeline.
Amgen discontinued some of its early-stage obesity pipelines (such as AMG 513) to focus heavily on MariTide, concentrating its risk on one candidate.
Third, for Moderna, risks include potential future share dilution from the $2 billion convertible bond issuance and a high cash burn rate, as it could take several years to fill the revenue gap left by the decline in COVID-19 vaccine demand.
Investment Perspective Summary
When fatigue builds up in the AI hardware value chain—represented by the Philadelphia Semiconductor Index (SOX)—the biotechnology and pharmaceutical sectors can serve as attractive rotation alternatives.
Investors should monitor individual pipeline milestones while watching for signs of stability in the US Dollar Index (DXY) and the Volatility Index (VIX).
For those seeking steady shareholder returns alongside defensive earnings growth, Amgen could be an attractive portfolio addition. For those looking for a dramatic valuation leap in next-generation cancer therapies, monitoring Moderna's high-risk, high-return momentum could be a viable strategy.
Investment Checklist
- **Q1. When is the release date for data from Amgen's obesity treatment MariTide maintenance therapy trial (SWITCH Phase 3)?**
- The SWITCH clinical trial of MariTide is a 52-week data analysis testing 8-week or quarterly dosing intervals in patients already taking weekly GLP-1 therapies. The topline final data release is expected to be announced at an upcoming medical conference.
- **Q2. What level of efficacy did Moderna's cancer vaccine, Intismeran, show when combined with Merck's Keytruda?**
- According to the 5-year follow-up Phase 2b trial (KEYNOTE-942) results, the combination therapy reduced the risk of cancer recurrence or death by 49% and lowered the risk of distant metastasis by 59% compared to Keytruda alone.
- **Q3. How significant is the impact of the patent expiration of Prolia, Amgen's existing key osteoporosis treatment?**
- Due to the launch of biosimilars after June 2025, Prolia's Q2 sales fell about 32% year-over-year to $759 million. However, Repatha is successfully replacing it, perfectly cushioning the revenue gap.
- **Q4. Are the terms of the $2 billion convertible bonds issued by Moderna favorable to shareholders?**
- Issued as zero-coupon (0%) bonds maturing in 2032, the short-term financial cost burden is extremely low. However, if they are converted into shares in large numbers in the future, the outstanding share count will increase, carrying potential dilution risk for existing shareholders.
- **Q5. Why does the biotech sector react more sensitively to drops in the US 10-Year Treasury Yield (US10Y)?**
- The value of biotech companies heavily relies on the future cash flows of pipeline products that may only materialize years down the road. When interest rates fall, the discount rate used to calculate the present value of future cash flows decreases, raising overall valuations.